A retrospective study for ALK positive Lung Cancer - The Clinical Benefits of Sequential Therapy using Crizotinib followed by Alectinib in Clinical Practice: A Multicenter Retrospective Study. - (WJOG9516L)

A retrospective study for ALK positive Lung Cancer - The Clinical Benefits of Sequential Therapy using Crizotinib followed by Alectinib in Clinical Practice: A Multicenter Retrospective Study. - (WJOG9516L) - A retrospective study for ALK positive Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028605

Enrollment

700

Registered

2017-08-09

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer (NSCLC)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Confirmed diagnosis with NSCLC pathologically. 2) Confirmed diagnosis with ALK rearranged by molecular analysis. 3) Received crizotinib and/or alectinib therapy between May 1, 2012 and Dec 31, 2016.

Exclusion criteria

Exclusion criteria: No prior exposure of ceritinib before crizotinib or alectinib, regardless of clinical trial or practice.

Design outcomes

Primary

Measure	Time frame
Combined time-treatment-failure (TTF) of crizotinib and alectinib	—

Secondary

Measure	Time frame
Overall survival (OS) Time to treatment failure (TTF) Progression-free survival (PFS) Combined PFS Objective response rate (ORR) TTF of chemotherapy	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results